{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:52Z","timestamp":1787022112258,"version":"build-2736575974"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"crossref","award":["8053-00026B"],"award-info":[{"award-number":["8053-00026B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004954","name":"Augustinus Foundation","doi-asserted-by":"crossref","award":["19-2759"],"award-info":[{"award-number":["19-2759"]}],"id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Grosserer L. F. Foghts Foundation","award":["21.746"],"award-info":[{"award-number":["21.746"]}]},{"DOI":"10.13039\/501100006197","name":"A.P. M\u00f8ller Foundation for the Advancement of Medical Science","doi-asserted-by":"crossref","award":["19-L-0057"],"award-info":[{"award-number":["19-L-0057"]}],"id":[{"id":"10.13039\/501100006197","id-type":"DOI","asserted-by":"crossref"}]},{"name":"T\u00f8mmerhandler Vilhelm Bangs Foundation","award":["07.02.2020"],"award-info":[{"award-number":["07.02.2020"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Non-invasive biomarkers of non-alcoholic fatty liver disease (NAFLD) supporting diagnosis and monitoring disease progression are urgently needed. The present study aimed to establish a bioinformatics pipeline capable of defining and validating NAFLD biomarker candidates based on paired hepatic global gene expression and plasma bioanalysis from individuals representing different stages of histologically confirmed NAFLD (no\/mild, moderate, more advanced NAFLD). Liver secretome gene signatures were generated in a patient cohort of 26 severely obese individuals with the majority having no or mild fibrosis. To this end, global gene expression changes were compared between individuals with no\/mild NAFLD and moderate\/advanced NAFLD with subsequent filtering for candidate gene products with liver-selective expression and secretion. Four candidate genes, including\n                    <jats:italic>LPA<\/jats:italic>\n                    (lipoprotein A),\n                    <jats:italic>IGFBP-1<\/jats:italic>\n                    (insulin-like growth factor-binding protein 1),\n                    <jats:italic>SERPINF2<\/jats:italic>\n                    (serpin family F member 2) and\n                    <jats:italic>MAT1A<\/jats:italic>\n                    (methionine adenosyltransferase 1A), were differentially expressed in moderate\/advanced NAFLD, which was confirmed in three independent RNA sequencing datasets from large, publicly available NAFLD studies. The corresponding gene products were quantified in plasma samples but could not discriminate among different grades of NAFLD based on NAFLD activity score.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    : We demonstrate a novel approach based on the liver transcriptome allowing for identification of secreted hepatic gene products as potential circulating diagnostic biomarkers of NAFLD. Using this approach in larger NAFLD patient cohorts may yield potential circulating biomarkers for NAFLD severity.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0275901","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T13:38:39Z","timestamp":1666186719000},"page":"e0275901","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity"],"prefix":"10.1371","volume":"17","author":[{"given":"Christoffer A.","family":"Hagemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Legart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias B.","family":"M\u00f8llerh\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik H.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete J.","family":"K\u00f8nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Helgstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming P.","family":"Hj\u00f8rne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Toxv\u00e6rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill L.","family":"Langhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urd L.","family":"Kielgast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-4468","authenticated-orcid":true,"given":"Lise L.","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"\u00c6gidius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer T. G.","family":"Rigbolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Jelsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-5034","authenticated-orcid":true,"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"pone.0275901.ref001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"key":"pone.0275901.ref002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"pone.0275901.ref003","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.3748\/wjg.v27.i23.3238","article-title":"Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis","volume":"27","author":"TK Seen","year":"2021","journal-title":"World J Gastroenterol"},{"key":"pone.0275901.ref004","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. [cited 13 Sep 2018]. doi: 10.1007\/s00125-016-3902-y","DOI":"10.1007\/s00125-016-3902-y"},{"key":"pone.0275901.ref005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach","volume":"13","author":"ME Rinella","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0275901.ref006","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"DE Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"pone.0275901.ref007","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"AJ Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"pone.0275901.ref008","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1155\/2014\/757929","article-title":"Biomarkers in nonalcoholic fatty liver disease","volume":"28","author":"MG Neuman","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"pone.0275901.ref009","article-title":"Plasma proteome profiling discovers novel proteins associated with non\u2010alcoholic fatty liver disease","volume":"15","author":"L Niu","year":"2019","journal-title":"Mol Syst Biol"},{"key":"pone.0275901.ref010","doi-asserted-by":"crossref","first-page":"942","DOI":"10.15252\/msb.20156297","article-title":"Revisiting biomarker discovery by plasma proteomics","volume":"13","author":"PE Geyer","year":"2017","journal-title":"Mol Syst Biol"},{"key":"pone.0275901.ref011","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/pmic.201200451","article-title":"The challenge of the proteome dynamic range and its implications for in-depth proteomics","volume":"13","author":"RA Zubarev","year":"2013","journal-title":"Proteomics"},{"key":"pone.0275901.ref012","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/hep.26661","article-title":"Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease","volume":"59","author":"CA Moylan","year":"2014","journal-title":"Hepatology"},{"key":"pone.0275901.ref013","first-page":"9","article-title":"Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease","author":"SA Hoang","year":"2019","journal-title":"Sci Rep"},{"key":"pone.0275901.ref014","first-page":"12","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","author":"O Govaere","year":"2020","journal-title":"Sci Transl Med"},{"key":"pone.0275901.ref015","first-page":"11","article-title":"Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD","author":"L Pantano","year":"2021","journal-title":"Sci Rep"},{"key":"pone.0275901.ref016","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study","volume":"46","author":"W Sun","year":"2016","journal-title":"Hepatology Research"},{"key":"pone.0275901.ref017","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"P Angulo","year":"2007","journal-title":"Hepatology"},{"key":"pone.0275901.ref018","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clnesp.2020.02.010","article-title":"Diagnostic of hepatic fibrosis with the XL probe of the Fibroscan versus biopsies in patients candidates to bariatric surgery","volume":"37","author":"C Barsamian","year":"2020","journal-title":"Clin Nutr ESPEN"},{"key":"pone.0275901.ref019","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1530-0277.2006.00295.x","article-title":"The alcohol use disorders identification test: an update of research findings","volume":"31","author":"DF Reinert","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"pone.0275901.ref020","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"DC Rockey","year":"2009","journal-title":"Hepatology"},{"key":"pone.0275901.ref021","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"MI Love","year":"2014","journal-title":"Genome Biol"},{"key":"pone.0275901.ref022","doi-asserted-by":"crossref","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","article-title":"The Reactome Pathway Knowledgebase","volume":"46","author":"A Fabregat","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"pone.0275901.ref023","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1093\/nar\/gkt111","article-title":"Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods","volume":"41","author":"L V\u00e4remo","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"pone.0275901.ref024","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/pmic.200400866","article-title":"A human proteome project with a beginning and an end","volume":"4","author":"I. Humphery-Smith","year":"2004","journal-title":"Proteomics"},{"key":"pone.0275901.ref025","doi-asserted-by":"crossref","DOI":"10.3390\/nu11081795","article-title":"Identification of the secreted proteins originated from primary human hepatocytes and HepG2 cells","volume":"11","author":"A Franko","year":"2019","journal-title":"Nutrients"},{"key":"pone.0275901.ref026","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis","volume":"75","author":"X Xiong","year":"2019","journal-title":"Mol Cell"},{"key":"pone.0275901.ref027","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/hep.22241","article-title":"A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients","volume":"47","author":"GM Campos","year":"2008","journal-title":"Hepatology"},{"key":"pone.0275901.ref028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1042\/BJ20121580","article-title":"Insight into S-Adenosylmethionine biosynthesis from the crystal structures of the human methionine adenosyltransferase catalytic and regulatory subunits","volume":"452","author":"N Shafqat","year":"2013","journal-title":"Biochemical Journal"},{"key":"pone.0275901.ref029","first-page":"4","article-title":"Comparing protein abundance and mRNA expression levels on a genomic scale","author":"D Greenbaum","year":"2003","journal-title":"Genome Biol"},{"key":"pone.0275901.ref030","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.4161\/cc.5.15.3101","article-title":"Systematic proteome and transcriptome analysis of stem cell populations","volume":"5","author":"RD Unwin","year":"2006","journal-title":"Cell Cycle"},{"key":"pone.0275901.ref031","first-page":"111","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","author":"N Perakakis","year":"2020","journal-title":"Metabolism"},{"key":"pone.0275901.ref032","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"RW Tipping","year":"2009","journal-title":"JAMA\u2014Journal of the American Medical Association"},{"key":"pone.0275901.ref033","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/er.2001-0033","article-title":"Cellular actions of the insulin-like growth factor binding proteins","volume":"23","author":"SM Firth","year":"2002","journal-title":"Endocr Rev"},{"key":"pone.0275901.ref034","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood-2003-12-4240","article-title":"A novel plasma proteinase potentiates \u03b12-antiplasmin inhibition of fibrin digestion","volume":"103","author":"KN Lee","year":"2004","journal-title":"Blood"},{"key":"pone.0275901.ref035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/1568016043356228","article-title":"\u03b12-Antiplasmin: Potential therapeutic roles in fibrin survival and removal","volume":"2","author":"KN Lee","year":"2004","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"key":"pone.0275901.ref036","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2353\/ajpath.2009.080850","article-title":"Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients","volume":"175","author":"F Caillot","year":"2009","journal-title":"American Journal of Pathology"},{"key":"pone.0275901.ref037","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/1535370215579161","article-title":"Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine","volume":"240","author":"M Noureddin","year":"2015","journal-title":"Exp Biol Med"},{"key":"pone.0275901.ref038","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/j.gastro.2017.01.015","article-title":"Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis","volume":"152","author":"C Alonso","year":"2017","journal-title":"Gastroenterology"},{"key":"pone.0275901.ref039","article-title":"Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Diseas","author":"M Meroni","year":"2021","journal-title":"Hepatol Commun"},{"key":"pone.0275901.ref040","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1210\/clinem\/dgaa792","article-title":"Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease","volume":"106","author":"TL Stanley","year":"2021","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"pone.0275901.ref041","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0149-2918(95)80048-4","article-title":"Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment","volume":"17","author":"M Malaguarnera","year":"1995","journal-title":"Clin Ther"},{"key":"pone.0275901.ref042","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0021-9150(94)90006-X","article-title":"Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis","volume":"105","author":"WL Gregory","year":"1994","journal-title":"Atherosclerosis"},{"key":"pone.0275901.ref043","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hep.23271","article-title":"Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease","volume":"51","author":"LN Bell","year":"2010","journal-title":"Hepatology"},{"key":"pone.0275901.ref044","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1053\/j.gastro.2013.07.047","article-title":"Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease","volume":"145","author":"SK Murphy","year":"2013","journal-title":"Gastroenterology"},{"key":"pone.0275901.ref045","first-page":"12","article-title":"S-adenosylmethionine upregulates the angiotensin receptor-binding protein ATRAP via the methylation of HuR in NAFLD","author":"T Guo","year":"2021","journal-title":"Cell Death Dis"},{"key":"pone.0275901.ref046","doi-asserted-by":"crossref","DOI":"10.1038\/srep24740","article-title":"Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD","volume":"6","author":"EM Pet\u00e4j\u00e4","year":"2016","journal-title":"Sci Rep"},{"key":"pone.0275901.ref047","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/00365521.2017.1379556","article-title":"IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD\u2013a pilot study","volume":"52","author":"H Hagstr\u00f6m","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"pone.0275901.ref048","article-title":"Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease","author":"J Pan","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"pone.0275901.ref049","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/jc.2006-0587","article-title":"Review: The role of insulin resistance in nonalcoholic fatty liver disease","volume":"91","author":"KM Utzschneider","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"pone.0275901.ref050","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1111\/j.1530-0277.2011.01547.x","article-title":"S-adenosyl-L-methionine treatment for alcoholic liver disease: A double-blinded, randomized, placebo-controlled trial","volume":"35","author":"V Medici","year":"2011","journal-title":"Alcohol Clin Exp Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T19:03:41Z","timestamp":1678302221000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275901"}},"subtitle":[],"editor":[{"given":"Pavel","family":"Strnad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0275901","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}